In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raised his price target …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics (NASDAQ:PGNX) with a $11 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Soligenix (OTC:SNGX) with a $5 price target, following today’s …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) and raised his price target to …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $19 price …
In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation (NASDAQ:MDVN) with a price target of …
